343.70MMarket Cap-3680P/E (TTM)
6.880High6.045Low547.16KVolume6.600Open6.750Pre Close3.47MTurnover1.35%Turnover RatioLossP/E (Static)56.25MShares7.66052wk High3.30P/B247.31MFloat Cap1.62052wk Low--Dividend TTM40.48MShs Float46.250Historical High--Div YieldTTM12.37%Amplitude1.180Historical Low6.335Avg Price1Lot Size
Black Diamond Therapeutics Stock Forum
NEWS
Black Diamond Therapeutics, Inc. presents real-world data at AACR Annual Meeting showcasing the potential of BDTX-1535, the most advanced fourth-generation oral TKI, to target a wide range of classical, non-classical, and C797S resistance EGFR mutations in NSCLC patients. The compound demonstrates potent inhibition of over 50 clinically relevant non-classical EGFR mutations and the C797S resistance mutation, offering a promising treatment option for EGF...
$Black Diamond Therapeutics(BDTX.US)$
$NWTN Inc(NWTN.US)$
$LiveWire Group(LVWR.US)$
No comment yet